Dean Fennell

Dean Fennell initially qualified with a first class degree in Pharmacology followed by Medicine and Surgery from University College London. After basic specialist training at UCL, Hammersmith, Brompton, Guy’s and St Thomas’ Hospitals in London he obtained Membership of the Royal College of Physicians, followed by a PhD in Oncology as a MRC Clinical research fellow in UCL. He completed training in Medical Oncology at St Bartholomew’s Hospital, and then undertook back-to-back Cancer Research UK Clinician Scientist Fellowships, until his current appointment in 2012. He was elected fellow of the Royal College of Physicians (London) in 2007. He served two terms on the board of the EORTC, leads a translational research laboratory and international clinical trials portfolio focused on translating novel precision medicine strategies from the lab to the clinic. He is chief investigator for the CONFIRM, VIM and MiST trials in relapsed mesothelioma, a member of the IASLC & European mesothelioma taskforce, past IMIG president/NCRI mesothelioma CSG chair. He is currently director of the new Leicester Mesothelioma Research programme focused on advancing effective therapy for mesothelioma. Prof. Fennell has over 100 publications in journals including New England Journal of Medicine, Nature, Lancet, Lancet Oncology, Proceedings of the National Academy of Science, Nature Communications, and Journal of the National Cancer Institute.

Education:
UCL
MB BS Medicine
Pharmacology (1st class), Medicine

UCL
BSc(Hons 1st class)

UCL
Doctor of Philosophy - PhD

Royal college of physicians (London)
MRCP Adult Medicine

Royal College of Physicians (London)
FRCP Medicine

Prizes and honours:

BSc 
1st year - Best Performance
2nd year - Heinz Schild Prize

MBBS
Biochemistry, Pharmacology, Neurology, Surgery, Clinical Pharmacology, Respiratory Medicine.

PhD 
American Society of Haematology award

Experience:

University of Leicester
Professor of Thoracic Medical Oncology
Feb 2012 – Present

University Hospitals of Leicester NHS Trust
Consultant physician, Thoracic Medical Oncology
2012 – Present
Consultant Physician, Clinical Trialist, Translational Researcher, International Key Opinion Leader in Mesothelioma & Lung Cancer,

Cancer Research UK Clinician Scientist, Consultant and Reader in Medical Oncology
2005 – 2012

Chairs, boards and steering groups:

2012 - President Elect, IMIG
2010, 2011 - IASLC Fellowships Committee
2010, 2011 - ASCO-NCI-EORTC Planning Committees
2010, 2008, 2006 - IMIG (Conference Chair 2008 & 2006)
2009 - AACR-NCI-EORTC Scientific Committee Conference
2004 - British Thoracic Oncology Group, former Faculty IASLC
Member - UKLCC Virtual MDT
IACR Council
EORTC lung group
NCRI lung studies group, mesothelioma subgroup and new agents group
CCRB Steering Committee
International panel for adenocarcinoma classification
MK0683-014-04 phase III vorinostat mesothelioma steering Scientific Committee

Most cited publications:

Tracking the evolution of non–small-cell lung cancer
M Jamal-Hanjani, GA Wilson, N McGranahan, NJ Birkbak, TBK Watkins, ...
New England Journal of Medicine 376 (22), 2109-2121 2017

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
C Abbosh, NJ Birkbak, GA Wilson, M Jamal-Hanjani, T Constantin, ...
Nature 545 (7655), 446-451 2017

Small-cell lung cancer
JP Van Meerbeeck, DA Fennell, DKM De Ruysscher
The Lancet 378 (9804), 1741-1755 2011

Allele-specific HLA loss and immune escape in lung cancer evolution
N McGranahan, R Rosenthal, CT Hiley, AJ Rowan, TBK Watkins, ...
Cell 171 (6), 1259-1271. e11 2017

Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer
B Delage, DA Fennell, L Nicholson, I McNeish, NR Lemoine, T Crook, ...
International journal of cancer 126 (12), 2762-2772 2010